Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010

Obesity

Volumn 23, Issue 8, 2015, Pages 1721-1728

  Xia, Ying ^a   Kelton, Christina M L ^a,b   Guo, Jeff J ^a   Bian, Boyang ^c   Heaton, Pamela C ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c HUMANA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; UNITED STATES; DRUG THERAPY; HISTORY; MIDDLE AGED; MORTALITY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTI-OBESITY AGENTS; DRUG THERAPY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; OBESITY; UNITED STATES; YOUNG ADULT;

EID: 84937413016     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21136     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Adult obesity facts: 2014. http://www.cdc.gov/obesity/data/adult.html. Accessed March 10, 2015.
2. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report: 1998. http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf. Accessed March 10, 2015.
3. Jia H, Lubetkin EI,. The impact of obesity on health-related quality-of-life in the general adult U.S. population. J Public Health 2005; 27: 156-164.
4. Finkelstein E, Trogdon J, Cohen JW, Dietz W,. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Affairs 2009; 28: 822-831.
5. Putnam JJ,. Cases of myxoedema and acromegalia treated with benefit by sheep's thyroids. Am J Med Sci 1893; 106: 125-148.
6. Lemke TL, Williams DA., Foye's Principles of Medicinal Chemistry, 7th Ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2013.
7. Li Z, Maglione M, Tu W, et al., Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
8. Centers for Disease Control and Prevention. Losing weight: what is healthy weight loss? 2011. Available at: http://www.cdc.gov/healthyweight/losing-weight/index.html. Accessed March 10, 2015.
9. Yanovski SZ, Yanovski, Long-term drug treatment for obesity: a systematic and clinical review. J Am Med Assoc 2014; 311: 74-86.
10. U.S. Department of Justice Drug Enforcement Administration. Controlled substances: 2015. http://www.deadiversion.usdoj.gov/schedules/orangebook/c-cs-alpha.pdf. Accessed March 8, 2015.
11. National Institutes of Health. What causes overweight and obesity: 2014. http://www.nhlbi.nih.gov/health/health-topics/topics/obe/causes.html. Accessed March 10, 2015.
12. American Medical Association. AMA adopts new policies on second day of voting at annual meeting. 2013. http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Accessed March 10, 2015.
13. Food and Drug Administration. FDA announces withdrawal of fenfluramine and dexfenfluramine (fen-phen). 1997. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed March 10, 2015.
14. Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. 2010 http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. Accessed March 10, 2015.
15. Food and Drug Administration. FDA drug safety communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. Accessed March 10, 2015.
16. LAWriter® Ohio Laws and Rules. 4731-11-04 Controlled substances: utilization for weight reduction: 2005. http://codes.ohio.gov/oac/4731-11-04. Accessed March 10, 2015.
17. Kansas Board of Healing Arts. 100-23-1. Treatment of obesity: 1998. http://www.ksbha.org/regulations/article23.shtml. Accessed March 10, 2015.
18. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1): S14-S80.
19. Centers for Disease Control and Prevention. 2010 NAMCS micro-data file documentation: 2012. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Dataset-Documentation/NAMCS/doc2010.pdf. Accessed March 10, 2015.
20. Centers for Disease Control and Prevention. 2010 NHAMCS micro-data file documentation: 2012. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Dataset-Documentation/NHAMCS/doc2010.pdf. Accessed March 10, 2015.
21. Siller AB, Tompkins L., The big four: analyzing complex sample survey data using SAS®, SPSS®, STATA®, and SUDAAN®. In Proceedings of the Thirty-first Annual SAS® San Francisco, CA:Users Group International Conference, 2006, pp. 26-29.
22. Stafford RS, Radley DC,. National trends in antiobesity medication use. Arch Intern Med 2003; 163: 1046-1050.
23. Hampp C, Kang EM, Borders-Hemphill V,. Use of prescription antiobesity drugs in the United States. Pharmacotherapy 2013; 33: 1299-1307.
24. United States Census Bureau. Population by age and sex: 2011. http://www.census.gov/population/age/data/2011comp.html. Accessed March 10, 2015.
25. Patterson L, Kee F, Hughes C, O'Reilly D,. The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study. BMC Public Health 2014; 14: 87.
26. Adipex-P [package insert]. Sellersville, PA: Teva Pharmaceuticals USA; 2012.
27. Meridia [package insert]. North Chicago, IL: Abbott Laboratories; 2010.
28. Golay A,. Metformin and body weight. Int J Obes 2007; 32: 61-72.
29. Khan LK, Serdula MK, Bowman BA, Williamson DF,. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med 2001; 134: 282-286.
30. Hendricks E, Rothman R, Greenway F,. How physician obesity specialists use drugs to treat obesity. Obesity 2009; 17: 1730-1735.
31. Stop Obesity Alliance. Medicaid fee-for-service treatment of obesity interventions-50 states and District of Columbia survey: 2013. http://www.stopobesityalliance.org/wp-content/themes/stopobesityalliance/pdfs/2013-Medicaid-FFS-Coverage-of-Obesity-Services.pdf. Accessed March 10, 2015.
32. Centers for Medicare & Medicaid Services. Medicare prescription drug benefit manual: 2010. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Chapter6.pdf. Accessed March 10, 2015.
33. Jensen MD, Ryan DH, Donato KA, et al., Guidelines (2013) for managing overweight and obesity in adults. Obesity 2014; 22 (S2): S1-S410.
34. Jensen MD, Ryan DH,. New obesity guidelines promise and potential. J Am Med Assoc 2014; 311: 23-24.
35. Apovian CM, Aronne LJ, Bessesen DH, et al., Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342-362.
36. Tsigos C, Hainer V, Basdevant A, et al., Management of obesity in adults: European clinical practice guidelines. Obesity Facts 2008; 1: 106-116.
37. Lau DC, Douketis JD, Morrison KM, et al., 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Can Med Assoc J 2007; 176: S1-S13.
38. Orexigen. EmpaticTM: 2015. http://www.orexigen.com/empatic-test.html. Accessed March 12, 2015.
39. Saniona. Saniona acquires clinical obesity asset from NeuroSearch: 2014. http://saniona.com/EN/saniona-acquires-clinical-obesity-asset-from-neurosearch/. Accessed March 12, 2015.
40. Transition. TT401 for type 2 diabetes and obesity: 2013. http://www.transitiontherapeutics.com/technology/tt401.php. Accessed March 10, 2015.